Chinese Hepatolgy ›› 2021, Vol. 26 ›› Issue (1): 51-54.

• Liver Cancer • Previous Articles     Next Articles

Efficacy and safety of TACE and nanoparticles in the treatment of portal hypertension in early-stage liver cancer

FANG Qi-lou1, NI Jian-xun1, FAN Hong-xing1, JIN Ge2   

  1. 1. Department of General Surgery, Liaoning Health Industry Group Fuxin Mine General Hospital, Fuxin 123000,China;
    2. Department of Pharmacology, Shenyang Medical College, Liaoning 110000, China
  • Received:2020-04-02 Online:2021-01-31 Published:2021-02-26
  • Contact: JIN Ge,Email:jinge1026@163.com

PDF (PC)

229

Abstract: Objective To investigate the clinical efficacy and safety of transarterial chemoembolization (TACE) combined with nanoparticles in the treatment of early-stage liver cancer complicated by portal hypertension.Methods Ninety-eight patients with early-stage liver cancer complicated by portal hypertension treated in our hospital from February 2013 to January 2018 were selected and divided into TACE group (45 cases) and combination therapy group (TACE combined with nanoparticle therapy, 53 cases). The efficacy of treatment, cancer recurrence rate and postoperative complication rate were compared between the 2 groups. The liver function and tumor factor indexes were compared before and 1 month after surgery in the 2 groups.Results (1) The Objective response rate (ORR) and disease control rate (DCR) were 58.49% and 86.79% in combination therapy group, 55.56% and 84.44% in TACE group, respectively. There was no statistical difference between the 2 groups (P>0.05). (2) There was no statistical difference in the levels of alanine aminotransferase or aspartate aminotransferase between the 2 groups before or 1 month after surgery (P>0.05). (3) There was no significant difference in carcinoembryonic antigen levels before or 1 month after surgery between the 2 groups (P>0.05). The level of vascular endothelial growth factor (VEGF) 1 month after surgery in combination therapy group was lower than that in TACE group (P<0.05). (4) The recurrence rates at 1 and 2 years after surgery in combination therapy group were lower than those in TACE group (P<0.05). (5) There was no significant difference in the rate of postoperative complications between the 2 groups (P>0.05).Conclusion TACE has good therapeutic effect on the early-stage liver cancer complicated by portal hypertension. Besides, nanoparticle therapy can significantly reduce the long-term recurrence rate after surgery. The reason may be that nanoparticle therapy can reduce the VEGF level in patients.

Key words: Transarterial chemoembolization, Nanoparticles, Early-stage liver cancer, Portal hypertension, Safety